Педиатрическая фармакология (Sep 2014)

PECULIARITIES OF EXTERNAL THERAPY OF ATOPIC DERMATITIS IN CHILDREN: ROLE OF METHYLPREDNISOLONE ACEPONATE

  • Yu. G. Levina,
  • A. A. Alekseeva,
  • E. A. Vishneva,
  • K. E. Efendieva,
  • A. Yu. Tomilova

DOI
https://doi.org/10.15690/pf.v11i5.1165
Journal volume & issue
Vol. 11, no. 5
pp. 52 – 58

Abstract

Read online

The article is dedicated to the issues of external therapy of atopic dermatitis in children. Atopic dermatitis is a chronic allergic inflammatory skin disease; in most cases, it is the first manifestation of atopic march. Timely and adequate pathogenetic external therapy of this disease using topical glucocorticosteroids (TGCSs) helps to quickly and effectively terminate symptoms of the disease and allergic inflammation of the skin. Steroid phobia, which is prevalent among parents of the patients, reduced adherence to the TGCS therapy. The authors analyzed results of the original studies of effectiveness and safety of TGCSs, present general recommendations on TGCS use in children with due regard to morphofunctional peculiarities of children’s skin and clinical‑pharmacological description of the TGCSs featuring the most favorable therapeutic index of 0.1% methylprednisolone aceponate. Methylprednisolone aceponate available in 4 pharmaceutical forms is the optimal drug of choice for atopic dermatitis in children over 4 months of age.

Keywords